Methods for prevention of ulcers and improving physiological performance

Abstract

Methods for preventing ulcers, such as gastric ulcers, in a mammal about to undergo stress that causes gastric ulcers and prior to occurrence of a gastric ulcer condition in the mammal involving administering a proton pump inhibitor (PPI) are disclosed and claimed.

1 - 20 . (canceled)  
     
     
         21 . A method for preventing occurrence of gastric ulcers in a mammal about to undergo stress that causes gastric ulcers and prior to occurrence of a gastric ulcer condition in the mammal, comprising administering to the mammal an effective amount of a proton pump inhibitor (PPI) prior to, and optionally during, the stress.  
     
     
         22 . The method of  claim 21  wherein the proton pump inhibitor (PPI) is omeprazole or esomeprazole.  
     
     
         23 . The method of  claim 22  wherein the proton pump inhibitor (PPI) is omeprazole.  
     
     
         24 . The method of  claim 23  wherein the administering is prior to and during the stress.  
     
     
         25 . The method of  claim 23  wherein the administering is daily.  
     
     
         26 . The method of  claim 23  wherein the gastric ulcers comprise gastrointestinal ulcers.  
     
     
         27 . The method of  claim 23  wherein the mammal is a human.  
     
     
         28 . The method of  claim 23  wherein the effective amount of omeprazole is 0.1 to 8 mg per kilogram body weight.  
     
     
         29 . The method of  claim 23  wherein the effective dose is about 50% of the usual dose for the treatment of ulcers in a mammal.  
     
     
         30 . The method of  claim 23  wherein the effective dose is about 25% of the usual dose for the treatment of ulcers in a mammal.  
     
     
         31 . The method of  claim 23  wherein the omeprazole is in the form of a formulation for controlled release.  
     
     
         32 . The method of  claim 23  wherein the administering is oral and the omeprazole is in a formulation for oral administration.  
     
     
         33 . The method of  claim 32  wherein the formulation is selected from the group consisting of oral solutions, oral suspensions, feed premix, pastes, gels, powder, granules, tablets, capsules and boli.  
     
     
         34 . The method of  claim 32  wherein the mammal is a human and the formulation is selected from the group consisting of oral solutions, oral suspensions, gels, tablets, capsules and powder.